318 related articles for article (PubMed ID: 14558672)
1. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
2. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
4. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Karavitaki N; Dobrescu R; Byrne JV; Grossman AB; Wass JA
Clin Endocrinol (Oxf); 2013 Aug; 79(2):217-23. PubMed ID: 23215960
[TBL] [Abstract][Full Text] [Related]
5. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
6. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
7. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
8. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.
Arafah BM
J Clin Endocrinol Metab; 1986 Jun; 62(6):1173-9. PubMed ID: 3009521
[TBL] [Abstract][Full Text] [Related]
9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
10. Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline.
Walia R; Bhansali A; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2011 Sep; 134(3):314-9. PubMed ID: 21985814
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
12. Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors.
Ratnasingam J; Karim N; Paramasivam SS; Ibrahim L; Lim LL; Tan AT; Vethakkan SR; Jalaludin A; Chan SP
Pituitary; 2015 Aug; 18(4):448-55. PubMed ID: 25134488
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
14. Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis.
Jahangiri A; Wagner JR; Han SW; Tran MT; Miller LM; Chen R; Tom MW; Ostling LR; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2016 Mar; 124(3):589-95. PubMed ID: 26252454
[TBL] [Abstract][Full Text] [Related]
15. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up.
Tsagarakis S; Grossman A; Plowman PN; Jones AE; Touzel R; Rees LH; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1991 May; 34(5):399-406. PubMed ID: 1647898
[TBL] [Abstract][Full Text] [Related]
16. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
17. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
[TBL] [Abstract][Full Text] [Related]
18. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
19. Pergolide as primary therapy for macroprolactinomas.
Orrego JJ; Chandler WF; Barkan AL
Pituitary; 2000 Dec; 3(4):251-6. PubMed ID: 11788013
[TBL] [Abstract][Full Text] [Related]
20. [Prolactinoma].
Glezer A; Bronstein MD
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
